PBP‐NPs containing HO‐1 inducers were injected intravenously once a week for 4 weeks and analyzed to demonstrate synergistic effects of fatty liver/adipose tissue dual‐targeting PBP‐NPs in the NASH model. Here, HMOX1 is linked to metabolic dysfunction-associated steatohepatitis.